We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a...
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals...
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq:...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers 2.5 mg dose restored normative...
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC...
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa...
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa...
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | -1.2 | -7.05882352941 | 17 | 17.1 | 15 | 10230 | 16.99022483 | DE |
12 | 0.9 | 6.04026845638 | 14.9 | 17.1 | 14.9 | 7728 | 16.17181116 | DE |
26 | 7.5 | 90.3614457831 | 8.3 | 17.1 | 8.3 | 3039 | 15.69757216 | DE |
52 | 7.8 | 97.5 | 8 | 17.1 | 7.2 | 4354 | 11.32086104 | DE |
156 | 8.9 | 128.985507246 | 6.9 | 17.1 | 5.55 | 4173 | 10.55310729 | DE |
260 | 8.9 | 128.985507246 | 6.9 | 17.1 | 5.55 | 4173 | 10.55310729 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions